UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY

Home

Download

Statistics

Examples

Help

Contact

	Kinase Fusion Gene Summary
	Kinase Fusion Gene Sample Information
	Kinase Fusion ORF Analysis
	Kinase Fusion Amino Acid Sequences
	Multiple Sequence Alignment of All Fusion Protein Isoforms
	Kinase Fusion Protein Functional Features
	Kinase Fusion Protein Structures
	Comparison of Fusion Protein Isoforms
	Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB
	pLDDT Scores and Difference Analysis of pLDDT Scores Between the Active Sites (Best) and Non-Active Sites.
	Ramachandran Plot of Kinase Fusion Protein Structure
	Potential Active Site Information
	Virtual Screening Results
	Kinase-Substrate Information
	Related Drugs with This Kinase Fusion Protein
	Related Disease with This Kinase Fusion Protein
	Clinical Trials of the Found Drugs/Small Molecules

Kinase Fusion Gene:TERT_ALK

Kinase Fusion Protein Summary

Kinase Fusion gene summary

Kinase Fusion partner gene information	Kinase Fusion gene name: TERT_ALK
	KinaseFusionDB ID: KFG6475
	FusionGDB2.0 ID: KFG6475
		Hgene	Tgene
	Gene symbol	TERT	ALK
	Gene ID	7015	238
	Gene name	telomerase reverse transcriptase	ALK receptor tyrosine kinase
	Synonyms	CMM9\|DKCA2\|DKCB4\|EST2\|PFBMFT1\|TCS1\|TP2\|TRT\|hEST2\|hTRT	ALK1\|CD246\|NBLST3
	Cytomap	5p15.33	2p23.2-p23.1
	Type of gene	protein-coding	protein-coding
	Description	telomerase reverse transcriptasetelomerase catalytic subunittelomerase-associated protein 2	ALK tyrosine kinase receptorCD246 antigenanaplastic lymphoma receptor tyrosine kinasemutant anaplastic lymphoma kinase
	Modification date	20240416	20240411
	UniProtAcc	O14746	Q3KRA9
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000310581, ENST00000296820, ENST00000334602, ENST00000508104, ENST00000522877,	ENST00000389048, ENST00000431873, ENST00000498037,
Context (manual curation of fusion genes in KinaseFusionDB)	PubMed: TERT [Title/Abstract] AND ALK [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	TERT	GO:0001172	RNA-templated transcription	19701182
Hgene	TERT	GO:0006278	RNA-templated DNA biosynthetic process	9398860
Hgene	TERT	GO:0007004	telomere maintenance via telomerase	9443919\|16043710\|17940095\|19701182\|21531765\|29695869
Hgene	TERT	GO:0007005	mitochondrion organization	21937513
Hgene	TERT	GO:0010629	negative regulation of gene expression	11927518
Hgene	TERT	GO:0022616	DNA strand elongation	16043710
Hgene	TERT	GO:0030422	siRNA processing	19701182
Hgene	TERT	GO:0031647	regulation of protein stability	24415760\|26194824
Hgene	TERT	GO:0032092	positive regulation of protein binding	24415760
Hgene	TERT	GO:0051000	positive regulation of nitric-oxide synthase activity	11927518
Hgene	TERT	GO:0070200	establishment of protein localization to telomere	25589350
Hgene	TERT	GO:0071897	DNA biosynthetic process	9398860
Hgene	TERT	GO:0140745	siRNA transcription	19701182
Hgene	TERT	GO:1904751	positive regulation of protein localization to nucleolus	24415760
Hgene	TERT	GO:2000773	negative regulation of cellular senescence	11927518
Tgene	ALK	GO:0007169	cell surface receptor protein tyrosine kinase signaling pathway	25605972\|30061385\|34646012
Tgene	ALK	GO:0016310	phosphorylation	9174053
Tgene	ALK	GO:0038083	peptidyl-tyrosine autophosphorylation	30061385\|34646012
Tgene	ALK	GO:0046777	protein autophosphorylation	9174053
Tgene	ALK	GO:0046777	protein autophosphorylation	9174053

Kinase Fusion gene breakpoints across TERT (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Kinase Fusion gene breakpoints across ALK (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Kinase Fusion Gene Sample Information

Kinase Fusion gene information.

Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Sample	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp
CCLE	KELLY	TERT	chr5	1264519	ALK	chr2	29606725
CCLE	KELLY	TERT	chr5	1266579	ALK	chr2	29606725

Top

Kinase Fusion ORF Analysis

Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB.

Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Seq length (transcript)	Seq length (amino acids)
ENST00000310581	ENST00000389048	TERT	chr5	1264519	ALK	chr2	29606725	7060	2197
ENST00000310581	ENST00000389048	TERT	chr5	1266579	ALK	chr2	29606725	6871	2134

Top

Kinase Fusion Amino Acid Sequences

For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq

>ENST00000310581_ENST00000389048_TERT_chr5_1264519_ALK_chr2_29606725_length(amino acids)=2197
MLRTWEALAPATPAMPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSC
LKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSC
AYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSW
AHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFL
LSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVA
APEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGV
GCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPAL
LTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPEL
YFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSS
SLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRT
LVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSWTVLQGRIGRPDNPFRVALEYISSGNRS
LSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPVGFYCNFEDGFCGWTQGTLSPHTPQWQV
RTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSLVLVENKTGKEQGRMVWHVAAYEGLSLW
QWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLFERNPNKELKPGENSPRQTPIFDPTVHW
LFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKGGKNTMMRSHGVSVLGIFNLEKDDMLYI
LVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPVPLIIAAGGGGRAYGAKTDTFHPERLEN
NSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGGGCSSGGGGGGYIGGNAASNNDPEMDGE
DGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSA
LVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEG
QVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAM
LDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTW
SFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGP
LVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVH
GSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVN

--------------------------------------------------------------

>ENST00000310581_ENST00000389048_TERT_chr5_1266579_ALK_chr2_29606725_length(amino acids)=2134
MLRTWEALAPATPAMPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSC
LKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSC
AYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSW
AHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFL
LSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVA
APEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGV
GCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPAL
LTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPEL
YFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSS
SLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLSW
TVLQGRIGRPDNPFRVALEYISSGNRSLSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPV
GFYCNFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSL
VLVENKTGKEQGRMVWHVAAYEGLSLWQWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLF
ERNPNKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKG
GKNTMMRSHGVSVLGIFNLEKDDMLYILVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPV
PLIIAAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGG
GCSSGGGGGGYIGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAE
DGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSIS
DLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILL
ELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKG
GCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNF
AIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVP
RGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLL

--------------------------------------------------------------

Multiple Sequence Alignment of All Fusion Protein Isoforms

Top

Kinase Fusion Protein Functional Features

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr5:/chr2:)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
TERT O14746	ALK Q3KRA9
FUNCTION: Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis. {ECO:0000269\|PubMed:14963003, ECO:0000269\|PubMed:15082768, ECO:0000269\|PubMed:15857955, ECO:0000269\|PubMed:17026956, ECO:0000269\|PubMed:17264120, ECO:0000269\|PubMed:17296728, ECO:0000269\|PubMed:17548608, ECO:0000269\|PubMed:19188162, ECO:0000269\|PubMed:19567472, ECO:0000269\|PubMed:19571879, ECO:0000269\|PubMed:19777057, ECO:0000269\|PubMed:9389643}.	FUNCTION: Probable dioxygenase that requires molecular oxygen, alpha-ketoglutarate and iron. {ECO:0000250}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page
* Minus value of BPloci means that the break pointn is located before the CDS.

- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt).

Partner

Hgeneene

Hbp

Tgeneene

Tbp

ENST

BPexon

TotalExon

Protein feature loci

BPloci

TotalLen

Feature

Note

- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt).

Partner

Hgeneene

Hbp

Tgeneene

Tbp

ENST

BPexon

TotalExon

Protein feature loci

BPloci

TotalLen

Feature

Note

Tgene

TERT

1264519

ALK

29606725

ENST00000310581

437_473

384

1621

Domain

Note=LDL-receptor class A

Tgene

TERT

1266579

ALK

29606725

ENST00000310581

437_473

384

1621

Domain

Note=LDL-receptor class A

Tgene

TERT

1264519

ALK

29606725

ENST00000310581

478_636

384

1621

Domain

Note=MAM 2;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00128

Tgene

TERT

1266579

ALK

29606725

ENST00000310581

478_636

384

1621

Domain

Note=MAM 2;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00128

Tgene

TERT

1264519

ALK

29606725

ENST00000310581

1116_1392

384

1621

Domain

Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159

Tgene

TERT

1266579

ALK

29606725

ENST00000310581

1116_1392

384

1621

Domain

Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159

Top

Kinase Fusion Protein Structures

CIF files of the predicted kinase fusion proteins
* Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format.

Kinase Fusion protein CIF link (fusion AA seq ID in KinaseFusionDB)	Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	AA seq	Len(AA seq)
PDB file >>>496_TERT_ALK	ENST00000310581	ENST00000389048	TERT	chr5	1266579	ALK	chr2	29606725	MLRTWEALAPATPAMPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSC LKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSC AYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSW AHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFL LSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVA APEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGV GCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPAL LTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPEL YFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSS SLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLSW TVLQGRIGRPDNPFRVALEYISSGNRSLSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPV GFYCNFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSL VLVENKTGKEQGRMVWHVAAYEGLSLWQWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLF ERNPNKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKG GKNTMMRSHGVSVLGIFNLEKDDMLYILVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPV PLIIAAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGG GCSSGGGGGGYIGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAE DGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSIS DLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILL ELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKG GCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNF AIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVP RGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLL	2134
3D view using mol* of 496_TERT_ALK

PDB file >>>TKFP_834_TERT_ALK	ENST00000310581	ENST00000389048	TERT	chr5	1264519	ALK	chr2	29606725	MLRTWEALAPATPAMPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSC LKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSC AYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSW AHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFL LSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVA APEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGV GCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPAL LTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPEL YFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSS SLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRT LVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSWTVLQGRIGRPDNPFRVALEYISSGNRS LSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPVGFYCNFEDGFCGWTQGTLSPHTPQWQV RTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSLVLVENKTGKEQGRMVWHVAAYEGLSLW QWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLFERNPNKELKPGENSPRQTPIFDPTVHW LFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKGGKNTMMRSHGVSVLGIFNLEKDDMLYI LVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPVPLIIAAGGGGRAYGAKTDTFHPERLEN NSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGGGCSSGGGGGGYIGGNAASNNDPEMDGE DGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSA LVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEG QVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAM LDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTW SFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGP LVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVH GSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVN	2197_TERT_ALK
PDB file >>>TKFP_835_TERT_ALK	ENST00000310581	ENST00000389048	TERT	chr5	1266579	ALK	chr2	29606725	MLRTWEALAPATPAMPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSC LKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSC AYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSW AHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFL LSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVA APEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGV GCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPAL LTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPEL YFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSS SLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLSW TVLQGRIGRPDNPFRVALEYISSGNRSLSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPV GFYCNFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSL VLVENKTGKEQGRMVWHVAAYEGLSLWQWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLF ERNPNKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKG GKNTMMRSHGVSVLGIFNLEKDDMLYILVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPV PLIIAAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGG GCSSGGGGGGYIGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAE DGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSIS DLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILL ELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKG GCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNF AIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVP RGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLL	2134_TERT_ALK
3D view using mol* of TKFP_835_TERT_ALK

Top

Comparison of Fusion Protein Isoforms

Superimpose the 3D Structures Among All Fusion Protein Isoforms
* Download the pdb file and open it from the molstar online viewer.

3D view using mol* of viewer/superimpose_isoforms/TKFP_834_TERT_ALK_vs_TKFP_835_TERT_ALK_superimposed.pdb.html

Comparison of the Secondary Structures of Fusion Protein Isoforms

./secondary_str/TKFP_834_TERT_ALK_vs_TKFP_835_TERT_ALK.png

Top

Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB

Abstract of the Multiple Sequence Alignment of the Longest Fusion Protein Sequence and Known Sequence from PDB Search Using Fusion Gene Names

Multiple Sequence Alignment of the Longest Fusion Protein Sequence and Known Sequence from PDB Search Using Fusion Gene Names

Superimpose the 3D Structures Between the Longest Fusion Protein and the Longest Known PDB

3D view using mol* of viewer/superimpose_pdbs/TERT_ALK_5IUG_superimposed.pdb.html
3D view using mol* of viewer/superimpose_pdbs/TERT_ALK_5IUH_superimposed.pdb.html
3D view using mol* of viewer/superimpose_pdbs/TERT_ALK_5IUI_superimposed.pdb.html

Top

pLDDT score distribution

all_data/KinaseFusionDB_T_Results/KinaseFusionDB_T_ViolinPlots/496_TERT_ALK.pngall_data/KinaseFusionDB_T_Results/KinaseFusionDB_T_ViolinPlots/TKFP_835_TERT_ALK_updated_violin_plot.png

pLDDT score distribution of the predicted fusion protein structures from AlphaFold2
* AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100.
* The blue color at the bottom marks the best active site residues.

496_TERT_ALK.png

TKFP_835_TERT_ALK.png

Top

Potential Active Site Information

The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite.

Kinase Fusion AA seq ID in KinaseFusionDB	Site score	Size	Dscore	Volume	Exposure	Enclosure	Contact	Phobic	Philic	Balance	Don/Acc	Residues
TKFP_835_TERT_ALK	1.027	268	1.008	667.135	0.504	0.738	0.955	0.596	1.151	0.518	0.582	Chain A: 1608,1609,1610,1611,1641,1673,1674,1676,1 677,1680,1681,1684,1762,1785,1786,1787,1788,1789,1 790,1791,1793,1794,1795,1796,1797,1798,1799,1801,1 802,1803,1804,1805,1806,1810,1814,1815,1817,1818,1 819,1820,1853

Binding site residues of the found PDBs.

PDB accession	AA sequence	Residue position
5IUG	ASN	1093
5IUG	PRO	1094
5IUG	ASN	1095
5IUG	TYR	1096
5IUG	SER	1097
5IUG	PHE	1098
5IUG	ALA	1099
5IUG	GLY	1100
5IUG	LYS	1101
5IUG	THR	1102
5IUG	SER	1103
5IUG	SER	1104
5IUG	ILE	1105
5IUG	SER	1106
5IUG	ASP	1107
5IUG	LEU	1108
5IUG	LYS	1109
5IUG	GLU	1110
5IUG	VAL	1111
5IUG	PRO	1112
5IUG	ARG	1113
5IUG	LYS	1114
5IUG	ASN	1115
5IUG	ILE	1116
5IUG	THR	1117
5IUG	LEU	1118
5IUG	ILE	1119
5IUG	ARG	1120
5IUG	GLY	1121
5IUG	LEU	1122
5IUG	GLY	1123
5IUG	GLY	1128
5IUG	GLU	1129
5IUG	VAL	1130
5IUG	TYR	1131
5IUG	GLU	1132
5IUG	GLY	1133
5IUG	GLN	1134
5IUG	VAL	1135
5IUG	SER	1136
5IUG	PRO	1144
5IUG	LEU	1145
5IUG	GLN	1146
5IUG	VAL	1147
5IUG	ALA	1148
5IUG	VAL	1149
5IUG	LYS	1150
5IUG	THR	1151
5IUG	LEU	1152
5IUG	PRO	1153
5IUG	GLU	1154
5IUG	VAL	1155
5IUG	CYS	1156
5IUG	SER	1157
5IUG	GLU	1158
5IUG	GLN	1159
5IUG	ASP	1160
5IUG	GLU	1161
5IUG	LEU	1162
5IUG	ASP	1163
5IUG	PHE	1164
5IUG	LEU	1165
5IUG	MET	1166
5IUG	GLU	1167
5IUG	ALA	1168
5IUG	LEU	1169
5IUG	ILE	1170
5IUG	ILE	1171
5IUG	SER	1172
5IUG	LYS	1173
5IUG	PHE	1174
5IUG	ASN	1175
5IUG	HIS	1176
5IUG	GLN	1177
5IUG	ASN	1178
5IUG	ILE	1179
5IUG	VAL	1180
5IUG	ARG	1181
5IUG	CYS	1182
5IUG	ILE	1183
5IUG	GLY	1184
5IUG	VAL	1185
5IUG	SER	1186
5IUG	LEU	1187
5IUG	GLN	1188
5IUG	SER	1189
5IUG	LEU	1190
5IUG	PRO	1191
5IUG	ARG	1192
5IUG	PHE	1193
5IUG	ILE	1194
5IUG	LEU	1195
5IUG	LEU	1196
5IUG	GLU	1197
5IUG	LEU	1198
5IUG	MET	1199
5IUG	ALA	1200
5IUG	GLY	1201
5IUG	GLY	1202
5IUG	ASP	1203
5IUG	LEU	1204
5IUG	LYS	1205
5IUG	SER	1206
5IUG	PHE	1207
5IUG	LEU	1208
5IUG	ARG	1209
5IUG	GLU	1210
5IUG	THR	1211
5IUG	ARG	1212
5IUG	PRO	1213
5IUG	ARG	1214
5IUG	PRO	1215
5IUG	SER	1220
5IUG	LEU	1221
5IUG	ALA	1222
5IUG	MET	1223
5IUG	LEU	1224
5IUG	ASP	1225
5IUG	LEU	1226
5IUG	LEU	1227
5IUG	HIS	1228
5IUG	VAL	1229
5IUG	ALA	1230
5IUG	ARG	1231
5IUG	ASP	1232
5IUG	ILE	1233
5IUG	ALA	1234
5IUG	CYS	1235
5IUG	GLY	1236
5IUG	CYS	1237
5IUG	GLN	1238
5IUG	TYR	1239
5IUG	LEU	1240
5IUG	GLU	1241
5IUG	GLU	1242
5IUG	ASN	1243
5IUG	HIS	1244
5IUG	PHE	1245
5IUG	ILE	1246
5IUG	HIS	1247
5IUG	ARG	1248
5IUG	ASP	1249
5IUG	ILE	1250
5IUG	ALA	1251
5IUG	ALA	1252
5IUG	ARG	1253
5IUG	ASN	1254
5IUG	CYS	1255
5IUG	LEU	1256
5IUG	LEU	1257
5IUG	THR	1258
5IUG	CYS	1259
5IUG	PRO	1260
5IUG	GLY	1261
5IUG	PRO	1262
5IUG	GLY	1263
5IUG	ARG	1264
5IUG	VAL	1265
5IUG	ALA	1266
5IUG	LYS	1267
5IUG	ILE	1268
5IUG	GLY	1269
5IUG	ASP	1270
5IUG	PHE	1271
5IUG	GLY	1272
5IUG	MET	1273
5IUG	ALA	1274
5IUG	GLY	1287
5IUG	CYS	1288
5IUG	ALA	1289
5IUG	MET	1290
5IUG	LEU	1291
5IUG	PRO	1292
5IUG	VAL	1293
5IUG	LYS	1294
5IUG	TRP	1295
5IUG	MET	1296
5IUG	PRO	1297
5IUG	PRO	1298
5IUG	GLU	1299
5IUG	ALA	1300
5IUG	PHE	1301
5IUG	MET	1302
5IUG	GLU	1303
5IUG	GLY	1304
5IUG	ILE	1305
5IUG	PHE	1306
5IUG	THR	1307
5IUG	SER	1308
5IUG	LYS	1309
5IUG	THR	1310
5IUG	ASP	1311
5IUG	THR	1312
5IUG	TRP	1313
5IUG	SER	1314
5IUG	PHE	1315
5IUG	GLY	1316
5IUG	VAL	1317
5IUG	LEU	1318
5IUG	LEU	1319
5IUG	TRP	1320
5IUG	GLU	1321
5IUG	ILE	1322
5IUG	PHE	1323
5IUG	SER	1324
5IUG	LEU	1325
5IUG	GLY	1326
5IUG	TYR	1327
5IUG	MET	1328
5IUG	PRO	1329
5IUG	TYR	1330
5IUG	PRO	1331
5IUG	SER	1332
5IUG	LYS	1333
5IUG	SER	1334
5IUG	ASN	1335
5IUG	GLN	1336
5IUG	GLU	1337
5IUG	VAL	1338
5IUG	LEU	1339
5IUG	GLU	1340
5IUG	PHE	1341
5IUG	VAL	1342
5IUG	THR	1343
5IUG	SER	1344
5IUG	GLY	1345
5IUG	GLY	1346
5IUG	ARG	1347
5IUG	MET	1348
5IUG	ASP	1349
5IUG	PRO	1350
5IUG	PRO	1351
5IUG	LYS	1352
5IUG	ASN	1353
5IUG	CYS	1354
5IUG	PRO	1355
5IUG	GLY	1356
5IUG	PRO	1357
5IUG	VAL	1358
5IUG	TYR	1359
5IUG	ARG	1360
5IUG	ILE	1361
5IUG	MET	1362
5IUG	THR	1363
5IUG	GLN	1364
5IUG	CYS	1365
5IUG	TRP	1366
5IUG	GLN	1367
5IUG	HIS	1368
5IUG	GLN	1369
5IUG	PRO	1370
5IUG	GLU	1371
5IUG	ASP	1372
5IUG	ARG	1373
5IUG	PRO	1374
5IUG	ASN	1375
5IUG	PHE	1376
5IUG	ALA	1377
5IUG	ILE	1378
5IUG	ILE	1379
5IUG	LEU	1380
5IUG	GLU	1381
5IUG	ARG	1382
5IUG	ILE	1383
5IUG	GLU	1384
5IUG	TYR	1385
5IUG	CYS	1386
5IUG	THR	1387
5IUG	GLN	1388
5IUG	ASP	1389
5IUG	PRO	1390
5IUG	ASP	1391
5IUG	VAL	1392
5IUG	ILE	1393
5IUG	ASN	1394
5IUG	THR	1395
5IUG	ALA	1396
5IUG	LEU	1397
5IUG	PRO	1398
5IUG	ILE	1399
5IUG	GLU	1400
5IUG	TYR	1401
5IUG	GLY	1402
5IUG	PRO	1403
5IUG	LEU	1404
5IUH	ASN	1093
5IUH	PRO	1094
5IUH	ASN	1095
5IUH	TYR	1096
5IUH	SER	1097
5IUH	PHE	1098
5IUH	ALA	1099
5IUH	GLY	1100
5IUH	LYS	1101
5IUH	THR	1102
5IUH	SER	1103
5IUH	SER	1104
5IUH	ILE	1105
5IUH	SER	1106
5IUH	ASP	1107
5IUH	LEU	1108
5IUH	LYS	1109
5IUH	GLU	1110
5IUH	VAL	1111
5IUH	PRO	1112
5IUH	ARG	1113
5IUH	LYS	1114
5IUH	ASN	1115
5IUH	ILE	1116
5IUH	THR	1117
5IUH	LEU	1118
5IUH	ILE	1119
5IUH	ARG	1120
5IUH	GLY	1121
5IUH	LEU	1122
5IUH	GLY	1123
5IUH	GLU	1129
5IUH	VAL	1130
5IUH	TYR	1131
5IUH	GLU	1132
5IUH	GLY	1133
5IUH	GLN	1134
5IUH	VAL	1135
5IUH	SER	1136
5IUH	GLY	1137
5IUH	PRO	1144
5IUH	LEU	1145
5IUH	GLN	1146
5IUH	VAL	1147
5IUH	ALA	1148
5IUH	VAL	1149
5IUH	LYS	1150
5IUH	THR	1151
5IUH	LEU	1152
5IUH	PRO	1153
5IUH	GLU	1154
5IUH	VAL	1155
5IUH	CYS	1156
5IUH	SER	1157
5IUH	GLU	1158
5IUH	GLN	1159
5IUH	ASP	1160
5IUH	GLU	1161
5IUH	LEU	1162
5IUH	ASP	1163
5IUH	PHE	1164
5IUH	LEU	1165
5IUH	MET	1166
5IUH	GLU	1167
5IUH	ALA	1168
5IUH	LEU	1169
5IUH	ILE	1170
5IUH	ILE	1171
5IUH	SER	1172
5IUH	LYS	1173
5IUH	PHE	1174
5IUH	ASN	1175
5IUH	HIS	1176
5IUH	GLN	1177
5IUH	ASN	1178
5IUH	ILE	1179
5IUH	VAL	1180
5IUH	ARG	1181
5IUH	CYS	1182
5IUH	ILE	1183
5IUH	GLY	1184
5IUH	VAL	1185
5IUH	SER	1186
5IUH	LEU	1187
5IUH	GLN	1188
5IUH	SER	1189
5IUH	LEU	1190
5IUH	PRO	1191
5IUH	ARG	1192
5IUH	PHE	1193
5IUH	ILE	1194
5IUH	LEU	1195
5IUH	LEU	1196
5IUH	GLU	1197
5IUH	LEU	1198
5IUH	MET	1199
5IUH	ALA	1200
5IUH	GLY	1201
5IUH	GLY	1202
5IUH	ASP	1203
5IUH	LEU	1204
5IUH	LYS	1205
5IUH	SER	1206
5IUH	PHE	1207
5IUH	LEU	1208
5IUH	ARG	1209
5IUH	GLU	1210
5IUH	THR	1211
5IUH	ARG	1212
5IUH	PRO	1213
5IUH	ARG	1214
5IUH	PRO	1215
5IUH	SER	1219
5IUH	SER	1220
5IUH	LEU	1221
5IUH	ALA	1222
5IUH	MET	1223
5IUH	LEU	1224
5IUH	ASP	1225
5IUH	LEU	1226
5IUH	LEU	1227
5IUH	HIS	1228
5IUH	VAL	1229
5IUH	ALA	1230
5IUH	ARG	1231
5IUH	ASP	1232
5IUH	ILE	1233
5IUH	ALA	1234
5IUH	CYS	1235
5IUH	GLY	1236
5IUH	CYS	1237
5IUH	GLN	1238
5IUH	TYR	1239
5IUH	LEU	1240
5IUH	GLU	1241
5IUH	GLU	1242
5IUH	ASN	1243
5IUH	HIS	1244
5IUH	PHE	1245
5IUH	ILE	1246
5IUH	HIS	1247
5IUH	ARG	1248
5IUH	ASP	1249
5IUH	ILE	1250
5IUH	ALA	1251
5IUH	ALA	1252
5IUH	ARG	1253
5IUH	ASN	1254
5IUH	CYS	1255
5IUH	LEU	1256
5IUH	LEU	1257
5IUH	THR	1258
5IUH	CYS	1259
5IUH	PRO	1260
5IUH	GLY	1261
5IUH	PRO	1262
5IUH	GLY	1263
5IUH	ARG	1264
5IUH	VAL	1265
5IUH	ALA	1266
5IUH	LYS	1267
5IUH	ILE	1268
5IUH	GLY	1269
5IUH	ASP	1270
5IUH	PHE	1271
5IUH	GLY	1272
5IUH	MET	1273
5IUH	ALA	1274
5IUH	CYS	1288
5IUH	ALA	1289
5IUH	MET	1290
5IUH	LEU	1291
5IUH	PRO	1292
5IUH	VAL	1293
5IUH	LYS	1294
5IUH	TRP	1295
5IUH	MET	1296
5IUH	PRO	1297
5IUH	PRO	1298
5IUH	GLU	1299
5IUH	ALA	1300
5IUH	PHE	1301
5IUH	MET	1302
5IUH	GLU	1303
5IUH	GLY	1304
5IUH	ILE	1305
5IUH	PHE	1306
5IUH	THR	1307
5IUH	SER	1308
5IUH	LYS	1309
5IUH	THR	1310
5IUH	ASP	1311
5IUH	THR	1312
5IUH	TRP	1313
5IUH	SER	1314
5IUH	PHE	1315
5IUH	GLY	1316
5IUH	VAL	1317
5IUH	LEU	1318
5IUH	LEU	1319
5IUH	TRP	1320
5IUH	GLU	1321
5IUH	ILE	1322
5IUH	PHE	1323
5IUH	SER	1324
5IUH	LEU	1325
5IUH	GLY	1326
5IUH	TYR	1327
5IUH	MET	1328
5IUH	PRO	1329
5IUH	TYR	1330
5IUH	PRO	1331
5IUH	SER	1332
5IUH	LYS	1333
5IUH	SER	1334
5IUH	ASN	1335
5IUH	GLN	1336
5IUH	GLU	1337
5IUH	VAL	1338
5IUH	LEU	1339
5IUH	GLU	1340
5IUH	PHE	1341
5IUH	VAL	1342
5IUH	THR	1343
5IUH	SER	1344
5IUH	GLY	1345
5IUH	GLY	1346
5IUH	ARG	1347
5IUH	MET	1348
5IUH	ASP	1349
5IUH	PRO	1350
5IUH	PRO	1351
5IUH	LYS	1352
5IUH	ASN	1353
5IUH	CYS	1354
5IUH	PRO	1355
5IUH	GLY	1356
5IUH	PRO	1357
5IUH	VAL	1358
5IUH	TYR	1359
5IUH	ARG	1360
5IUH	ILE	1361
5IUH	MET	1362
5IUH	THR	1363
5IUH	GLN	1364
5IUH	CYS	1365
5IUH	TRP	1366
5IUH	GLN	1367
5IUH	HIS	1368
5IUH	GLN	1369
5IUH	PRO	1370
5IUH	GLU	1371
5IUH	ASP	1372
5IUH	ARG	1373
5IUH	PRO	1374
5IUH	ASN	1375
5IUH	PHE	1376
5IUH	ALA	1377
5IUH	ILE	1378
5IUH	ILE	1379
5IUH	LEU	1380
5IUH	GLU	1381
5IUH	ARG	1382
5IUH	ILE	1383
5IUH	GLU	1384
5IUH	TYR	1385
5IUH	CYS	1386
5IUH	THR	1387
5IUH	GLN	1388
5IUH	ASP	1389
5IUH	PRO	1390
5IUH	ASP	1391
5IUH	VAL	1392
5IUH	ILE	1393
5IUH	ASN	1394
5IUH	THR	1395
5IUH	ALA	1396
5IUH	LEU	1397
5IUH	PRO	1398
5IUH	ILE	1399
5IUH	GLU	1400
5IUH	TYR	1401
5IUH	GLY	1402
5IUH	PRO	1403
5IUH	LEU	1404
5IUI	MET	1089
5IUI	THR	1090
5IUI	ASP	1091
5IUI	TYR	1092
5IUI	ASN	1093
5IUI	PRO	1094
5IUI	ASN	1095
5IUI	TYR	1096
5IUI	SER	1097
5IUI	PHE	1098
5IUI	ALA	1099
5IUI	GLY	1100
5IUI	LYS	1101
5IUI	THR	1102
5IUI	SER	1103
5IUI	SER	1104
5IUI	ILE	1105
5IUI	SER	1106
5IUI	ASP	1107
5IUI	LEU	1108
5IUI	LYS	1109
5IUI	GLU	1110
5IUI	VAL	1111
5IUI	PRO	1112
5IUI	ARG	1113
5IUI	LYS	1114
5IUI	ASN	1115
5IUI	ILE	1116
5IUI	THR	1117
5IUI	LEU	1118
5IUI	ILE	1119
5IUI	ARG	1120
5IUI	GLY	1121
5IUI	LEU	1122
5IUI	GLY	1123
5IUI	HIS	1124
5IUI	GLY	1125
5IUI	ALA	1126
5IUI	PHE	1127
5IUI	GLY	1128
5IUI	GLU	1129
5IUI	VAL	1130
5IUI	TYR	1131
5IUI	GLU	1132
5IUI	GLY	1133
5IUI	GLN	1134
5IUI	VAL	1135
5IUI	SER	1136
5IUI	GLY	1137
5IUI	PRO	1142
5IUI	SER	1143
5IUI	PRO	1144
5IUI	LEU	1145
5IUI	GLN	1146
5IUI	VAL	1147
5IUI	ALA	1148
5IUI	VAL	1149
5IUI	LYS	1150
5IUI	THR	1151
5IUI	LEU	1152
5IUI	PRO	1153
5IUI	GLU	1154
5IUI	VAL	1155
5IUI	CYS	1156
5IUI	SER	1157
5IUI	GLU	1158
5IUI	GLN	1159
5IUI	ASP	1160
5IUI	GLU	1161
5IUI	LEU	1162
5IUI	ASP	1163
5IUI	PHE	1164
5IUI	LEU	1165
5IUI	MET	1166
5IUI	GLU	1167
5IUI	ALA	1168
5IUI	LEU	1169
5IUI	ILE	1170
5IUI	ILE	1171
5IUI	SER	1172
5IUI	LYS	1173
5IUI	PHE	1174
5IUI	ASN	1175
5IUI	HIS	1176
5IUI	GLN	1177
5IUI	ASN	1178
5IUI	ILE	1179
5IUI	VAL	1180
5IUI	ARG	1181
5IUI	CYS	1182
5IUI	ILE	1183
5IUI	GLY	1184
5IUI	VAL	1185
5IUI	SER	1186
5IUI	LEU	1187
5IUI	GLN	1188
5IUI	SER	1189
5IUI	LEU	1190
5IUI	PRO	1191
5IUI	ARG	1192
5IUI	PHE	1193
5IUI	ILE	1194
5IUI	LEU	1195
5IUI	LEU	1196
5IUI	GLU	1197
5IUI	LEU	1198
5IUI	MET	1199
5IUI	ALA	1200
5IUI	GLY	1201
5IUI	GLY	1202
5IUI	ASP	1203
5IUI	LEU	1204
5IUI	LYS	1205
5IUI	SER	1206
5IUI	PHE	1207
5IUI	LEU	1208
5IUI	ARG	1209
5IUI	GLU	1210
5IUI	THR	1211
5IUI	ARG	1212
5IUI	PRO	1213
5IUI	ARG	1214
5IUI	PRO	1215
5IUI	SER	1216
5IUI	GLN	1217
5IUI	PRO	1218
5IUI	SER	1219
5IUI	SER	1220
5IUI	LEU	1221
5IUI	ALA	1222
5IUI	MET	1223
5IUI	LEU	1224
5IUI	ASP	1225
5IUI	LEU	1226
5IUI	LEU	1227
5IUI	HIS	1228
5IUI	VAL	1229
5IUI	ALA	1230
5IUI	ARG	1231
5IUI	ASP	1232
5IUI	ILE	1233
5IUI	ALA	1234
5IUI	CYS	1235
5IUI	GLY	1236
5IUI	CYS	1237
5IUI	GLN	1238
5IUI	TYR	1239
5IUI	LEU	1240
5IUI	GLU	1241
5IUI	GLU	1242
5IUI	ASN	1243
5IUI	HIS	1244
5IUI	PHE	1245
5IUI	ILE	1246
5IUI	HIS	1247
5IUI	ARG	1248
5IUI	ASP	1249
5IUI	ILE	1250
5IUI	ALA	1251
5IUI	ALA	1252
5IUI	ARG	1253
5IUI	ASN	1254
5IUI	CYS	1255
5IUI	LEU	1256
5IUI	LEU	1257
5IUI	THR	1258
5IUI	CYS	1259
5IUI	PRO	1260
5IUI	GLY	1261
5IUI	PRO	1262
5IUI	GLY	1263
5IUI	ARG	1264
5IUI	VAL	1265
5IUI	ALA	1266
5IUI	LYS	1267
5IUI	ILE	1268
5IUI	GLY	1269
5IUI	ASP	1270
5IUI	PHE	1271
5IUI	GLY	1272
5IUI	MET	1273
5IUI	ALA	1274
5IUI	ARG	1275
5IUI	ASP	1276
5IUI	ILE	1277
5IUI	TYR	1278
5IUI	ARG	1279
5IUI	ALA	1280
5IUI	GLY	1286
5IUI	GLY	1287
5IUI	CYS	1288
5IUI	ALA	1289
5IUI	MET	1290
5IUI	LEU	1291
5IUI	PRO	1292
5IUI	VAL	1293
5IUI	LYS	1294
5IUI	TRP	1295
5IUI	MET	1296
5IUI	PRO	1297
5IUI	PRO	1298
5IUI	GLU	1299
5IUI	ALA	1300
5IUI	PHE	1301
5IUI	MET	1302
5IUI	GLU	1303
5IUI	GLY	1304
5IUI	ILE	1305
5IUI	PHE	1306
5IUI	THR	1307
5IUI	SER	1308
5IUI	LYS	1309
5IUI	THR	1310
5IUI	ASP	1311
5IUI	THR	1312
5IUI	TRP	1313
5IUI	SER	1314
5IUI	PHE	1315
5IUI	GLY	1316
5IUI	VAL	1317
5IUI	LEU	1318
5IUI	LEU	1319
5IUI	TRP	1320
5IUI	GLU	1321
5IUI	ILE	1322
5IUI	PHE	1323
5IUI	SER	1324
5IUI	LEU	1325
5IUI	GLY	1326
5IUI	TYR	1327
5IUI	MET	1328
5IUI	PRO	1329
5IUI	TYR	1330
5IUI	PRO	1331
5IUI	SER	1332
5IUI	LYS	1333
5IUI	SER	1334
5IUI	ASN	1335
5IUI	GLN	1336
5IUI	GLU	1337
5IUI	VAL	1338
5IUI	LEU	1339
5IUI	GLU	1340
5IUI	PHE	1341
5IUI	VAL	1342
5IUI	THR	1343
5IUI	SER	1344
5IUI	GLY	1345
5IUI	GLY	1346
5IUI	ARG	1347
5IUI	MET	1348
5IUI	ASP	1349
5IUI	PRO	1350
5IUI	PRO	1351
5IUI	LYS	1352
5IUI	ASN	1353
5IUI	CYS	1354
5IUI	PRO	1355
5IUI	GLY	1356
5IUI	PRO	1357
5IUI	VAL	1358
5IUI	TYR	1359
5IUI	ARG	1360
5IUI	ILE	1361
5IUI	MET	1362
5IUI	THR	1363
5IUI	GLN	1364
5IUI	CYS	1365
5IUI	TRP	1366
5IUI	GLN	1367
5IUI	HIS	1368
5IUI	GLN	1369
5IUI	PRO	1370
5IUI	GLU	1371
5IUI	ASP	1372
5IUI	ARG	1373
5IUI	PRO	1374
5IUI	ASN	1375
5IUI	PHE	1376
5IUI	ALA	1377
5IUI	ILE	1378
5IUI	ILE	1379
5IUI	LEU	1380
5IUI	GLU	1381
5IUI	ARG	1382
5IUI	ILE	1383
5IUI	GLU	1384
5IUI	TYR	1385
5IUI	CYS	1386
5IUI	THR	1387
5IUI	GLN	1388
5IUI	ASP	1389
5IUI	PRO	1390
5IUI	ASP	1391
5IUI	VAL	1392
5IUI	ILE	1393
5IUI	ASN	1394
5IUI	THR	1395
5IUI	ALA	1396
5IUI	LEU	1397
5IUI	PRO	1398
5IUI	ILE	1399
5IUI	GLU	1400

Top

Ramachandran Plot of Kinase Fusion Protein Structure

Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide.

496_TERT_ALK_ramachandran.png

TKFP_835_TERT_ALK_ramachandran.png

Top

Virtual Screening Results

Distribution of the average docking score across all approved kinase inhibitors.
Distribution of the number of occurrence across all approved kinase inhibitors.

5'-kinase fusion protein case

3'-kinase fusion protein case

Top

Drug information from DrugBank of the top 20 interacting small molecules.
* The detailed information of individual kinase inhibitors are available in the download page.

Fusion gene name info

Drug

Docking score

Glide g score

Glide energy

Top

Kinase-Substrate Information of TERT_ALK

Phosphorylation target of the kinase
(phosphosite, 03-17-2024)

Kinase	Kinase UniProt Acc	Kinase species	Substrate	Substrate UniProt Acc	Substrate phosphorylated residues	Substrate phosphorylated sites (+/-7AA)	Domain
ALK	Q9UM73	human	ALK	Q9UM73	Y1604	tAPGAGHyEDTILkS
ALK	Q9UM73	human	ELP3	Q9H9T3	Y202	GHtSNNIyEAVkySE	Radical_SAM
ALK	Q9UM73	human	ALK	Q9UM73	Y1278	FGMARDIyRAsyyRK	PK_Tyr_Ser-Thr
ALK	Q9UM73	human	CDK9	P50750	Y19	FCDEVSkyEkLAkIG
ALK	Q9UM73	human	SFPQ	P23246	Y293	RRPGEktyTQRCRLF
ALK	Q9UM73	human	ATIC	P31939	Y104	RVVACNLyPFVkTVA	MGS
ALK	Q9UM73	human	SRCIN1	Q9C0H9	Y396	LVKGEGLyADPyGLL
ALK	Q9UM73	human	STAT3	P40763	Y705	DPGsAAPyLktKFIC
ALK	Q9UM73	human	PTPN11	Q06124	Y580	REDsARVyENVGLMQ
ALK	Q9UM73	human	PBK	Q96KB5	Y74	NPICNDHyRsVyQkR	Pkinase
ALK	Q9UM73	human	VASP	P50552	Y39	AFSRVQIyHNPtANs	WH1
ALK	Q9UM73	human	PTPN11	Q06124	Y542	sKRkGHEytNIKysL
ALK	Q9UM73	human	GRB2	P62993	Y160	QVPQQPtyVQALFDF

Biological Network Integration of This Kinase and Substrates
(GeneMANIA website)

Enriched GO biological processes of the phosphorylation target genes of the kinase

Kinase

GOID

GO term

P.adjust

Top

Related Drugs to TERT_ALK

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Distribution of the number of studies mentioning TERT-ALK and kinase inhibitors the PubMed Abstract (04-01-2024)

Fusion gene - drug pair 1

Fusion gene - drug pair 2

PMID

Publication date

DOI

Study title

Top

Related Diseases to TERT_ALK

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Related diseases from the literature mentioned this fusion gene and drug.
(PubMed, 04-01-2024)

MeSH ID

MeSH term

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Tgene	ALK	C0007131	Non-Small Cell Lung Carcinoma	28	CGI;CTD_human
Tgene	ALK	C0027819	Neuroblastoma	13	CGI;CTD_human;ORPHANET
Tgene	ALK	C0152013	Adenocarcinoma of lung (disorder)	8	CGI;CTD_human
Tgene	ALK	C2751681	NEUROBLASTOMA, SUSCEPTIBILITY TO, 3	8	CLINGEN;UNIPROT
Tgene	ALK	C0206180	Ki-1+ Anaplastic Large Cell Lymphoma	6	CGI;CTD_human
Tgene	ALK	C0334121	Inflammatory Myofibroblastic Tumor	4	CGI;CTD_human;ORPHANET
Tgene	ALK	C0018199	Granuloma, Plasma Cell	3	CTD_human
Tgene	ALK	C0007621	Neoplastic Cell Transformation	2	CTD_human
Tgene	ALK	C0027627	Neoplasm Metastasis	2	CTD_human
Tgene	ALK	C0238463	Papillary thyroid carcinoma	2	ORPHANET

Top

Clinical Trials of the Found Drugs/Small Molecules

Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024)

Clinical Trials from clinicaltrials.gov (06-17-2024)

Fusion Gene

Kinase Inhibitor

NCT ID

Study Status

Phases

Disease

# Enrolment

Date